Dr. Meeks on the Importance of p53 and Rb1 in Bladder Cancer

Joshua J. Meeks, MD, PhD
Published: Thursday, Jan 24, 2019



Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the importance of p53 and Rb1 in bladder cancer.

P53 is not a biomarker, although it is present in over 70% of muscle-invasive tumors, says Meeks. The same frequency is found in patients with T1 tumors. P53 plays an integral role in bladder cancer. As was reflected in genetic models in mice, it was discovered that a patient is going to lose p53 and Rb1 expression in almost all of these tumors.

As the field progresses, subtypes will become more prominent, explains Meeks. Currently, the 5 subtypes are luminal papillary, true luminal, luminal-infiltrated, basal, and neuronal. As physicians uncover more about these tumors, subtyping will become more important to the prognostication and prediction of certain therapies—both chemotherapy and immunotherapy, he concludes.
SELECTED
LANGUAGE


Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the importance of p53 and Rb1 in bladder cancer.

P53 is not a biomarker, although it is present in over 70% of muscle-invasive tumors, says Meeks. The same frequency is found in patients with T1 tumors. P53 plays an integral role in bladder cancer. As was reflected in genetic models in mice, it was discovered that a patient is going to lose p53 and Rb1 expression in almost all of these tumors.

As the field progresses, subtypes will become more prominent, explains Meeks. Currently, the 5 subtypes are luminal papillary, true luminal, luminal-infiltrated, basal, and neuronal. As physicians uncover more about these tumors, subtyping will become more important to the prognostication and prediction of certain therapies—both chemotherapy and immunotherapy, he concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x